It is the question almost every patient eventually asks, usually somewhere around the six-month mark, when the clothes fit better and the labs look sharper: do I have to stay on this forever? Sooner or later, most people on semaglutide or tirzepatide want to know what happens if they stop — whether the results hold, whether the appetite comes roaring back, and whether there is a way to step down without undoing the work.

It is a fair question, and it deserves a straight answer rather than a sales pitch. The honest version is this: the published evidence consistently shows that when GLP-1 therapy stops, most of the lost weight returns over the following year, and many of the metabolic improvements drift back toward where they started. That is not a failure of discipline. It is the predictable behavior of a chronic condition when the treatment for it is withdrawn.

But "most" is not "all," and the picture is more nuanced than the headlines suggest. Below is what the research actually shows, why the body responds the way it does, and what a thoughtful maintenance plan looks like for patients here in Tarzana and across the San Fernando Valley.

The short answer

Across the major randomized trials, stopping a GLP-1 medication is followed by a steady return of appetite and a gradual regain of weight — typically most of it, though usually not quite all of it. The trajectory is predictable enough that researchers have now modeled it mathematically. Ongoing treatment, paired with real behavioral support, is what has been shown to hold the results.

What the research actually shows

Semaglutide: the STEP 1 trial extension

The clearest data on semaglutide withdrawal comes from the STEP 1 trial extension, published by Wilding and colleagues in Diabetes, Obesity and Metabolism in 2022. Participants lost a mean of 17.3% of body weight over 68 weeks on once-weekly semaglutide 2.4 mg plus lifestyle intervention. After treatment was withdrawn, they regained 11.6 percentage points of that loss by week 120 — roughly two-thirds of what they had lost — finishing the study period about 5.6% below their starting weight. Cardiometabolic improvements seen during treatment also reverted toward baseline for most measured variables.

Tirzepatide: the SURMOUNT-4 trial

SURMOUNT-4, published in JAMA in December 2023, tested the same question with tirzepatide. After 36 weeks of open-label treatment, participants were randomized either to continue tirzepatide or switch to placebo. Over the following 52 weeks, the withdrawal group regained a mean of 14% of body weight, while the group that continued lost an additional 6.7% — ending at roughly 26% total mean weight reduction from study entry. A later post hoc analysis published in JAMA Internal Medicine found that participants who regained the most weight also saw the greatest reversal of their earlier cardiometabolic gains.

The bigger picture: pooled data across trials

In March 2026, a systematic review and nonlinear meta-regression published in eClinicalMedicine pooled six randomized trials covering 3,236 participants to model the shape of weight regain after GLP-1 cessation. At one year post-cessation, roughly 60% of the weight lost during treatment had been regained. Extrapolating beyond 52 weeks, the authors estimated that regain plateaus at about 75% of the weight lost on treatment — meaning some benefit tends to persist long-term, but it is substantially attenuated.

Two things are worth pulling out of that finding. First, regain is gradual and decelerating, not a cliff — which means there is a window to intervene. Second, the plateau sits below pre-treatment weight for most people. Stopping does not automatically erase everything.

Why the weight comes back — and why it is not willpower

GLP-1 and dual GIP/GLP-1 agonists work in large part by acting on appetite regulation: slowing gastric emptying, increasing satiety, and quieting the food-related signaling that drives intake. When the medication is cleared, those effects fade and hunger signaling returns to its prior set point.

Layered on top of that is the well-documented metabolic adaptation that follows any significant weight loss — reduced energy expenditure and shifts in appetite-regulating hormones that persist well after the weight is gone. The body actively defends its previous weight. That physiology does not care how the weight was lost.

This is precisely why, in its first global guideline on GLP-1 therapies for obesity — released 1 December 2025 — the World Health Organization framed obesity as "a chronic disease that can be treated with comprehensive and lifelong care," and issued a conditional recommendation for the long-term use of liraglutide, semaglutide, and tirzepatide in adults, alongside intensive behavioral support. WHO also explicitly noted that data on maintenance and discontinuation strategies remain limited — an important caveat for anyone being promised a tidy exit plan.

The body-composition problem most people miss

Weight is a crude measure, and it hides the change that matters most after stopping treatment. Weight lost during a rapid caloric deficit is a mix of fat mass and lean mass. Weight regained afterward tends to be preferentially fat, particularly without a sustained resistance-training stimulus and adequate protein intake.

The practical implication: it is entirely possible to end up at the same number on the scale as before treatment with a less favorable ratio of fat to muscle than you started with. That matters for metabolic rate, insulin sensitivity, strength, and how you look and feel — none of which a bathroom scale can tell you.

This is one of the strongest arguments for tracking body composition analysis rather than weight alone, both during treatment and through any transition off it. If you are earlier in your journey, our guide on protecting lean mass during GLP-1 weight loss covers the training and nutrition side in more depth.

What else changes besides the number on the scale

Weight is the visible marker, but the trials consistently show that other measures move with it. In the STEP 1 extension, improvements in cardiometabolic risk factors seen at week 68 largely reverted toward baseline by week 120. The SURMOUNT-4 post hoc analysis found the same pattern with tirzepatide: the more weight regained, the greater the reversal of earlier improvements.

That is why ongoing lab testing matters through a transition. Periodic bloodwork gives you objective early warning about metabolic drift well before you would notice it any other way.

Is stopping ever the right decision?

Sometimes, yes. Patients discontinue for many legitimate reasons — side effects that do not resolve, cost, supply issues, pregnancy planning, a change in medical circumstances, or simply a considered decision that continued treatment is not right for them. None of that is a failure.

The distinction that matters clinically is between stopping abruptly and unsupported, and transitioning deliberately with a plan and follow-up. The evidence on regain says nothing about whether you should stop. It says a great deal about what to have in place if you do.

One more point worth saying plainly: any change to a prescription medication should be made with the prescribing clinician, not independently. Dose adjustments, tapering approaches, and maintenance strategies are individual medical decisions, and the evidence base for them is still developing.

How to protect your results through a transition

1. Plan the exit before you take it

The regain curve is gradual, which means the months immediately after stopping are the highest-leverage window. Decide in advance what your monitoring cadence will be, what your check-in triggers are, and who you will call if the trend turns. A transition without follow-up is not a plan.

2. Defend your muscle first

Resistance training and adequate protein are the primary tools for keeping lean mass while your appetite regulation shifts. This is the single highest-return behavior in the whole transition, and it needs to be established before you stop, not scrambled together afterward.

3. Measure body composition, not just weight

Regular InBody scanning shows you whether the trend is fat or muscle, and it shows it long before the mirror or the scale does. That distinction changes what you do next — a two-pound gain in muscle and a two-pound gain in fat call for opposite responses.

4. Keep the labs going

Continue periodic bloodwork through the transition period rather than discontinuing monitoring at the same time you discontinue treatment. Objective markers give you the earliest possible signal.

5. Check for what else might be working against you

Weight regulation is not driven by a single system. Thyroid function, sleep quality, stress, and sex hormone status all influence body composition and energy. If something feels disproportionately hard, it is worth investigating rather than assuming it is a motivation problem. For some patients, that means a closer look at hormone optimization and TRT as part of the broader picture.

6. Weigh yourself regularly

Research from the National Weight Control Registry, which tracks adults who have maintained substantial weight loss long-term, has consistently found that frequent self-weighing is associated with better maintenance, while reducing self-weighing frequency is associated with greater regain. It functions as an early alarm. High levels of regular physical activity — around an hour a day for many registry participants — is the other consistent thread.

7. Make recovery sustainable

The people who keep training are the people who recover well enough to keep showing up. That is the practical case for making recovery a scheduled part of the week rather than an afterthought — whether that is the infrared sauna, the cold plunge, or a full contrast therapy session in our Wellness Lounge. Consistency in the gym is what protects lean mass, and recovery is what protects consistency.

A note on skin after significant weight loss

Patients who lose a meaningful amount of weight often find that skin laxity, rather than fat, is what bothers them most at the end. That is a separate concern from metabolic maintenance and has its own set of non-surgical options — our Venus Legacy radiofrequency treatments in the Contour Lounge are designed for exactly that: tightening and smoothing skin without surgery or downtime.

How we approach maintenance at Contour Medical Clinic

Medical weight loss at Contour Medical Clinic in Tarzana is physician-supervised from the first consultation onward, and maintenance is treated as part of the program rather than an afterthought. That means comprehensive diagnostic bloodwork, InBody body composition tracking so progress is measured in fat and muscle rather than pounds, and a plan built around your labs, your goals, and your life — not a template.

Being housed inside Club Contour Studios means the clinical side and the recovery side sit under one roof on Ventura Blvd. We serve patients throughout Tarzana, Encino, Woodland Hills, and Sherman Oaks.

Frequently asked questions

Will I regain all the weight if I stop?

The pooled trial data suggests most people regain a majority of what they lost — about 60% within a year in the 2026 eClinicalMedicine meta-regression, plateauing at roughly 75% over a longer horizon. Individual results vary considerably, and the plateau typically sits below pre-treatment weight.

How quickly does the weight come back?

Gradually rather than suddenly. The meta-regression modeled a decelerating curve with a half-life of roughly 23 weeks, meaning regain is fastest early and slows over time. That early period is where intervention matters most.

Can I switch to a lower or less frequent maintenance dose instead of stopping?

Some clinicians do use reduced maintenance dosing, but the World Health Organization's 2025 guideline specifically flags that high-quality evidence on maintenance and discontinuation strategies is still limited. This is a decision to make with your prescribing physician based on your individual response and medical history — not something to attempt independently.

Does the hunger come back right away?

Appetite regulation returns as the medication clears. Many patients notice hunger and food-related thoughts returning before the scale moves, which is one reason having a plan in place beforehand matters.

Does stopping mean I failed?

No. The World Health Organization classifies obesity as a chronic, relapsing disease, and regain after treatment withdrawal is a physiological response, not a character judgment. The framing that matters is what comes next.

Talk it through before you change anything

If you are on a GLP-1 and thinking about what comes next — or you are considering starting and want to understand the long-term picture before you do — that conversation is worth having with a physician who knows your labs and your history.

Request a medical weight loss consultation at Contour Medical Clinic in Tarzana, or call (818) 214-9607. You can also learn more about our medical weight loss program, or read our detailed guides to semaglutide and tirzepatide.

This article is for general educational purposes and is not medical advice. It does not establish a physician-patient relationship. Do not start, stop, or adjust any prescription medication without consulting your prescribing clinician.

Written by: Contour Medical Clinic Editorial Team